What Is Chronic Immune Thrombocytopenia (ITP)?
Apr 28, 2022
Source: Cainiu Health
Dr. Zhang Jianbin
Introduction
Chronic immune thrombocytopenic purpura (ITP) is primarily characterized by bleeding symptoms, which are relatively mild but tend to recur. Patients develop petechiae or ecchymoses on the skin or mucous membranes—initially appearing on the extremities and gradually spreading to other areas. Mucosal bleeding may manifest as oral bleeding, gingival bleeding, or hematuria; female patients often experience menorrhagia and may present with signs of anemia.
Chronic Immune Thrombocytopenic Purpura (ITP) is an autoimmune disorder caused by dysregulation of the body’s immune system. It poses a threat to physical health and warrants serious attention. So, what exactly is chronic immune thrombocytopenic purpura?
What Is Chronic Immune Thrombocytopenic Purpura?
Chronic immune thrombocytopenic purpura is an immune-mediated hemorrhagic disorder characterized by a marked reduction in platelet count due to platelet destruction exceeding the bone marrow’s compensatory capacity. The disease often has an insidious onset; some patients report a preceding upper respiratory tract infection.
The predominant clinical manifestation of chronic ITP is bleeding, which tends to be relatively mild but recurrent. Patients commonly develop petechiae or ecchymoses on the skin or mucous membranes—initially appearing on the extremities and subsequently spreading to other areas. Mucosal bleeding may present as oral bleeding, gingival bleeding, or hematuria; female patients may experience menorrhagia, often accompanied by symptoms of anemia. The disease course is protracted, frequently lasting for several years without spontaneous remission, necessitating long-term treatment.
This is a hematologic disorder associated with immune dysfunction and is characterized by a prolonged course and frequent relapses. During treatment, age and disease severity must be carefully considered, and medications that inhibit platelet function should be avoided. In cases of severe bleeding, hemostatic agents such as carbazochrome (Anluoxue) or etamsylate (Zhixuemin) may be administered; fresh plasma transfusion may be required when necessary. If platelet counts remain persistently low after 4–6 weeks of medical therapy, surgical intervention should be considered. We hope this information is helpful to you. Wishing you good health and happiness!
